Back to Search Start Over

Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase.

Authors :
Kitagawa M
Okabe T
Ogino H
Matsumoto H
Suzuki-Takahashi I
Kokubo T
Higashi H
Saitoh S
Taya Y
Yasuda H
Source :
Oncogene [Oncogene] 1993 Sep; Vol. 8 (9), pp. 2425-32.
Publication Year :
1993

Abstract

We screened cdc2 kinase inhibitors from cultured mediums of micro organisms using purified mouse cyclin B-cdc2 kinase and a specific substrate peptide for cdc2 kinase. A selective inhibitor of cdc2 kinase was isolated from the cultured medium of Aspergillus species F-25799, and identified as butyrolactone I. Butyrolactone I inhibited cdc2 and cdk2 kinases but it had little effect on mitogen-activated protein kinase, protein kinase C, cyclic-AMP dependent kinase, casein kinase II, casein kinase I or epidermal growth factor-receptor tyrosine kinase. Its inhibitory effect was found to be due to competition with ATP. Butyrolactone I selectively inhibited the H1 histone phosphorylation in nuclear extracts. It also inhibited the phosphorylation of the product of retinoblastoma susceptibility gene in nuclear extracts and intact cells. Thus butyrolactone I should be very useful for elucidating the function of cdc2 and cdk2 kinases in cell cycle regulation.

Details

Language :
English
ISSN :
0950-9232
Volume :
8
Issue :
9
Database :
MEDLINE
Journal :
Oncogene
Publication Type :
Academic Journal
Accession number :
8395680